Healthcare Stocks

Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

 Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a review by ...

Read More...
Imugene Onboards Leading Surgical Oncologist to OV SAB; Completes $24.6 million placement

Imugene Onboards Leading Surgical Oncologist to OV SAB; Completes $24.6 million placement

Australia-based clinical stage immuno-oncology player, Imugene Limited (ASX: IMU) has recently announced the appointment of Surgeon Scientist, Dr. Rebecca Auer to its newly formed OV (oncolytic virotherapy) Scientific Advisory Board. Dr. Auer is t...

Read More...
Imugene Received Oversubscribed Placement Commitments to Raise $24.6 Million

Imugene Received Oversubscribed Placement Commitments to Raise $24.6 Million

Clinical-stage immuno-oncology player, Imugene Limited (ASX: IMU) recently notified that it has received firm commitments for a capital raising of up to $24.6 million that involves Placement of up to 683 million ordinary shares to sophisticated and p...

Read More...
Imugene Announces Completion of Clinical Grade GMP Batches by CF33 Oncolytic Virus Constructs

Imugene Announces Completion of Clinical Grade GMP Batches by CF33 Oncolytic Virus Constructs

In a recent ASX update, Australian headquartered Imugene Limited (ASX: IMU) has notified that CF33 oncolytic virus CheckVacc and Vaxinia constructs have completed clinical grade GMP batches at the manufacturing facility, City of Hope Center for Biome...

Read More...
Another Feather in Imugene’s Cap; Completes Acquisition of Oncolytic Virus CF33

Another Feather in Imugene’s Cap; Completes Acquisition of Oncolytic Virus CF33

Imugene Limited (ASX: IMU) jumped 18 per cent on ASX following the completion of oncolytic virus CF33 and Vaxinia Pty Ltd acquisition on 18th November 2019. IMU closed the trading session at $0.053 with ~259 million shares in rotation on 18th Novemb...

Read More...
Biotech player, Imugene Soars 27% on ASX; Glance Through Key Developments

Biotech player, Imugene Soars 27% on ASX; Glance Through Key Developments

Clinical-stage biotech player Imugene Limited (ASX: IMU) soared ~27 per cent on the ASX today, settling the day?s trade at $0.033 on 11th November 2019. The stock has delivered a substantial return of ~53 per cent in the last six months, driven by si...

Read More...
Imugene Limited Receives $4.13 Million R&D Tax Refund from Australian Government

Imugene Limited Receives $4.13 Million R&D Tax Refund from Australian Government

Australian immuno-oncology company, Imugene Limited (ASX: IMU) is developing a pipeline of mimotope-based B-cell immunotherapies against oncology targets that could replace or be used in combination with monoclonal antibodies. The company intends to ...

Read More...
Lens through Imugene’s September 2019 Quarterly 4C Report

Lens through Imugene’s September 2019 Quarterly 4C Report

Biotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology player that develops novel immunotherapies to treat and eradicate cancerous tumours. The company?s unique platform technologies hold the pot...

Read More...
Imugene Commends City of Hope Researchers on Receiving US Department of Defense Grant

Imugene Commends City of Hope Researchers on Receiving US Department of Defense Grant

As per latest update from Imugene Limited (ASX: IMU), the prominent City of Hope researchers have received a Grant of USD 564,173 from the US Department of Defense to study the company?s Oncolytic Virotherapy (OV) CF33 in gastric cancer. Marking a s...

Read More...
Imugene Released Program Update on Oncolytic Virus CF33’s Phase 1 Clinical Trial Plans

Imugene Released Program Update on Oncolytic Virus CF33’s Phase 1 Clinical Trial Plans

ASX-listed clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) has released an update on the preliminary clinical development plan for the intended exclusive license of the patents encompassing the oncolytic virus technology, CF33. The co...

Read More...
Imugene Hires Professor Yuman Fong to Lead Oncolytic Virotherapy Scientific Advisory Board

Imugene Hires Professor Yuman Fong to Lead Oncolytic Virotherapy Scientific Advisory Board

Australia-based clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is involved in the development of various new and novel immunotherapies that attempt to stimulate the patient?s immune system to eradicate and treat tumours. Imugene?s un...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK